HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Clarification Of Law On Citizen Petitions Could Bring Antitrust Scrutiny

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission wants to clarify through case law that repeated petitioning of the government could bring antitrust enforcement, even if petitioners make scientific and regulatory arguments

You may also be interested in...



Adams’ Suit Could Delay ANDA For URL/Mutual’s Mucinex Generic

A lawsuit filed by Adams Respiratory Therapeutics could bring a stay of up to 30 months on FDA's approval of Mutual Pharmaceuticals and United Research Laboratories' application for a generic version of Adams' Mucinex extended-release expectorant product

Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny

The introduction of certain follow-on brand drugs as the original product nears patent expiration could raise anticompetitive concerns at the Federal Trade Commission, according to FTC Commissioner Pamela Harbour

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel